Gilead Sciences Inc
NASDAQ:GILD
During the last 3 months Gilead Sciences Inc insiders have not bought any shares, and sold 29.3m USD worth of shares. The stock price has increased by 13% over this period (open performance analysis).
The last transaction was made on
Apr 15, 2025
by
Dickinson Andrew D
(Chief Financial Officer)
, who
sold
266k USD
worth of GILD shares.
During the last 3 months Gilead Sciences Inc insiders have not bought any shares, and sold 29.3m USD worth of shares. The stock price has increased by 13% over this period (open performance analysis).
The last transaction was made on
Apr 15, 2025
by
Dickinson Andrew D
(Chief Financial Officer)
, who
sold
266k USD
worth of GILD shares.
Gilead Sciences Inc
Glance View
Gilead Sciences Inc., established in 1987, embarked on its mission with a resolute focus on innovative therapeutic advancements. Nestled in the biotech haven of Foster City, California, Gilead pioneered a path that would see it evolve into a global biopharmaceutical powerhouse. The company’s nucleus is its commitment to discovering, developing, and delivering therapies for diseases with unmet medical needs. Its product portfolio reflects this dedication, notably dominated by groundbreaking advancements in antiviral therapies, particularly for HIV/AIDS, hepatitis B, and hepatitis C. Over the years, its robust research and development engine, fueled by a continual reinvestment of earnings, propelled it to the forefront of tackling complex medical challenges. Its strategic acquisitions, like the pivotal purchase of Pharmasset in 2011, underpinned its ascent in the hepatitis C treatment arena, highlighting its aptitude for identifying and integrating synergistic growth opportunities. Financially, Gilead generates its revenue through the commercialization of its pharmaceutical portfolio. It thrives on a model where its novel therapies, once developed and approved, are sold to healthcare providers and systems. The landscape of antiviral treatments, primarily the revolutionary HIV regimen and hepatitis C cures like Harvoni and Sovaldi, serves as the backbone of its revenue stream. Meanwhile, Gilead's ventures into oncology and inflammatory diseases through strategic acquisitions and partnerships aim to diversify its portfolio beyond infectious diseases. The intricate process from innovation to distribution underscores Gilead’s proficient use of its clinical expertise and market acumen to address both expanding global health needs and shareholder demands, ensuring its enduring presence in the volatile seas of the biotech industry.
What is Insider Trading?
Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.
While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.
Why is Insider Trading Important?
It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.
However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.
Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
You don't have any saved screeners yet